OPEN END TURBO OPTIONSSCHEIN SHORT - ASTRAZENECA | Market Closed - BOERSE MUENCHEN 11:55:16 17/05/2024 pm IST | ||
| 0.96 EUR | +5.61% |
|
| Current month | -7.69% | ||
| 1 month | -58.50% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.96 | +5.61% |
| 16/24/16 | 0.909 | +4.48% |
| 15/24/15 | 0.87 | +11.54% |
| 14/24/14 | 0.78 | +11.43% |
| 13/24/13 | 0.7 | +7.69% |
Real-time BOERSE MUENCHEN
Last update May 17, 2024 at 11:55 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | Goldman Sachs |
| WKN | GG1S44 |
| ISIN | DE000GG1S445 |
| Date issued | 03/01/2024 |
| Strike | 12,890 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.48 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.06 € |
|---|---|
| Lowest since issue | 0.578 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.9
USD
Average target price
167.6
USD
Spread / Average Target
+8.90%
- Stock Market
- Certificates
- Certificat
